Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Similar documents
Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Haematology, Oncology and Palliative Care Directorate.

MEDICAL NECESSITY GUIDELINE

Working Formulary January 2013 Oncology Chemotherapy Regimens

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

National Cancer Drugs Fund List - Approved

Cancer drug approvals for paediatric indications (n=43)

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The AngCN Antiemetic Guidelines

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Emetogenicity level 1. Emetogenicity level 2

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

MASCC Guidelines for Antiemetic control: An update

CCC Chemotherapy Protocols V9.0

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

Guidelines for the Use of Anti-Emetics with Chemotherapy

Antiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy

National Cancer Drugs Fund List Ver4.4

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

Disease Site Sub-Disease Site Intent Regimen Code Regimen Details Status (as of October 17, 2017) Breast Not Applicable Adjuvant / Curative

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

COME HOME Innovative Oncology Business Solutions, Inc.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

National Cancer Drugs Fund List Ver4.0

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25

Northern Cancer Alliance

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

CLINICAL TRIALS ACC. Jul 2016

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

National Cancer Drugs Fund List Ver2.1

ANTIEMETIC GUIDELINES: MASCC/ESMO

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines

Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting

See Important Reminder at the end of this policy for important regulatory and legal information.

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Guideline Update on Antiemetics

Standard Regimens for Haematology

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

For Health Professionals Who Care For Cancer Patients

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

See Important Reminder at the end of this policy for important regulatory and legal information.

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

For Health Professionals Who Care For Cancer Patients

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

General Authorization Criteria for ALL Agents and Indications:

Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults

THE DUDLEY GROUP NHS FOUNDATION TRUST FOI

Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

Index. Note: Page numbers of article titles are in boldface type.

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Hazardous Medication List

Pharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF)

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

Targeted Cancer Therapies

CancerPACT Cancer Patients Alliance for Clinical Trials

For Health Professionals Who Care For Cancer Patients EDITOR S CHOICE

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)

Chapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:

Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Triple Negative Breast Cancer: Part 2 A Medical Update

Bladder Cancer Pathways (Urothelial)

Acute Lymphocytic Leukemia

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Bladder Cancer (Urothelial) Pathways

An introduction to the Essential Medicines concept: balancing innovation with public health priorities

NICE TA Adherence Check List

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

Chemotherapy Treatment Algorithms for Urology Cancer

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Chemotherapy 101 for Radiation Oncology Workers

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Update on antiemetics, what is new and future directions. Karin Jordan University of Halle

DRUG PROPERTIES YOU NEED TO KNOW

CancerPACT Cancer Patients Alliance for Clinical Trials

Contents Trials. Dose guidelines. Calvert formula Issue Date: January Author: No: Copy. Pagee 1 of 21. Issue.

European consortium study on the availability of anti-neoplastic medicines

Subject: Palonosetron Hydrochloride (Aloxi )

8. Malignant disease and immunosuppression

Transcription:

Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin (EP) Therapy Gynaecology 267 PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy Gynaecology 266 Afatinib Monotherapy Lung 221 25/02/2018 Regorafenib Monotherapy Gastrointestinal 244 CARBOplatin (AUC 5-6) and Weekly 08/04/2018 PACLitaxel 80mg/m2 Therapy Gynaecology 308 CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy Gynaecology 303 CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy Lung 304 Gefitinib Monotherapy Lung 220 Irinotecan Monotherapy - 21 days Gastrointestinal 213 Nab-PACLitaxel (Abraxane) Monotherapy- 21 day cycle Breast 230 Pemetrexed Monotherapy Lung 222 Topotecan Monotherapy-5 day Gynaecology 311 Lung 311 Topotecan Monotherapy-Weekly Gynaecology 312 Weekly CARBOplatin and PACLitaxel Therapy with Radiotherapy Lung 309 14/04/2018 Radium 223 Therapy Genitourinary 257 15/04/2018 Abiraterone and Prednisolone Genitourinary 103 Aflibercept-14 days Gastrointestinal 238 03/05/2018 Bosutinib Monotherapy Leukaemia/BMT 224 CARBOplatin + Oral Etoposide Lung 319 CISplatin/5-FU Therapy Head & Neck 314 DOCEtaxel Monotheray 50mg/m2 Monotherapy-14 day Genitourinary 313 DOCEtaxel/CISplatin/5-FU + Chemoradiation Head & Neck 323 DOCEtaxel/CISplatin/5-FU + Radiotherapy Head & Neck 324 Everolimus and Exemestane Therapy Breast 322 Everolimus Monotherapy Genitourinary 320 Neuroendocrine 320 Intravenous Vinorelbine Leukaemia/BMT 232 Intravenous Vinorelbine Monotherapy- 7days Leukaemia/BMT 232

Neoadjuvant DOCEtaxel/CISplatin/5-FU + 03/05/2018 Chemoradiation + Surgery Head & Neck 315 Pemetrexed and CISplatin Therapy Lung 317 Ruxolitinib Monotherapy Leukaemia/BMT 229 Sorafenib Therapy Gastrointestinal 294 Genitourinary 294 Head & Neck 294 Capecitabine/Oxaliplatin (XELOX) 03/06/2018 Therapy Gastrointestinal 321 FOLFIRINOX Therapy Gastrointestinal 329 Pemetrexed and CARBOplatin Therapy Lung 318 Sunitnib 37.5mg Therapy Neuroendocrine 327 Sunitnib 50mg Therapy Sarcoma 325 Temsirolimus Monotherapy Genitourinary 326 Sunitinib 50mg Therapy Genitourinary 325 08/06/2018 Ipilimumab Monotherapy Skin/Melanoma 105 09/06/2018 Pembrolizumab Therapy Skin/Melanoma 347 CARBOplatin AUC (1.5) Chemoradiation 20/06/2018 Therapy-7 days Head & Neck 332 Cetuximab (14 days) and Irinotecan (14 days) Therapy Gastrointestinal 331 Cetuximab (7 days) and Irinotecan (14 days) Therapy Gastrointestinal 330 CISplatin, Methotrexate and Vinblastine Therapy Genitourinary 337 Dose Dense DOXOrubicin, Cyclophosphamide followed by PACLitaxel (14 days) and Trastuzumab Therapy Breast 316 Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy Gynaecology 264 Exemestane Monotherapy Breast 376 Imatinib Therpay-GIST Sarcoma 335 Pegylated Liposomal DOXOrubicin (CAELYX) Gynaecology 205 Pegylated Liposomal DOXOrubicin (CAELYX) 28 days Breast 205 Temozolomide Recurrent Therapy Neuro-oncology 342 Temozolomide with RT and Adjuvant Therapy Neuro-oncology 334 Vinorelbine and CISplatin Therapy-28 days Lung 343 27/06/2018 Brentuximab vedotin Monotherapy Leukaemia/BMT 234 Lymphoma and Mye 234 30/06/2018 Enzalutamide Monotherapy Leukaemia/BMT 233

30/06/2018 Pertuzumab + Trastuzumab + DOCEtaxel Breast 204 Bortezomib, Melphalan and 08/08/2018 Prednisolone Lymphoma and Mye 275 Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy Lymphoma and Mye 274 Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone Weekly Therapy Lymphoma and Mye 299 16/09/2018 Pomalidomide and Dexamethasone Lymphoma and Mye 245 21/10/2018 Axitinib Monotherapy Genitourinary 104 Tamoxifen Monotherapy Breast 253 23/10/2018 FOLFIRI + Cetuximab Therapy Gastrointestinal 328 01/11/2018 CISplatin and Teysuno-28 day cycle Gastrointestinal 235 11/11/2018 ABVD Therapy Lymphoma and Mye 290 epirubicin, CISplatin and Capecitabine (ECX) Therapy Gastrointestinal 380 Exemestane Monotherapy Breast 376 Fulvestrant Therapy Breast 361 Letrozole Monotherapy Breast 371 Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy Gynaecology 375 Trabectedin Monotherapy Sarcoma 374 16/11/2018 Anastrozole Monotherapy Breast 254 CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer 01/12/2018 Therapy Breast 348 Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy Breast 381 Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy Breast 378 Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy Breast 377 20/12/2018 Ceritinib Monotherapy Lung 340 CISplatin (100mg/m2) with Radiotherapy (RT) Head & Neck 387 DOXOrubicin (60) and Ifosfamide Therapy Sarcoma 391 DOXOrubicin (60mg/m2) Therapy Gastrointestinal 386 DOXOrubicin (75) and Ifosfamide Therapy Sarcoma 392 Gemcitabine + Capecitabine Therapy Gastrointestinal 384

20/12/2018 Oral Etoposide Therapy Lung 388 Ponatinib Therapy Leukaemia/BMT 302 05/01/2019 Idelalisib and Ofatumumab Therapy Leukaemia/BMT 390 Idelalisib and rituximab Therapy Leukaemia/BMT 389 Idelalisib Monotherapy Lymphoma and Mye 291 11/01/2019 Capecitabine Monotherapy Breast 216 Gastrointestinal 216 Dabrafenib Monotherapy Skin/Melanoma 237 Lapatinib and Capecitabine Breast 217 Vandetanib Monotherapy Head & Neck 242 18/01/2019 Lapatinib and Capecitabine Breast 217 01/02/2019 Nindetanib Therapy Lung 372 Trifluridine and Tipiracil (Lonsurf ) Therapy Gastrointestinal 382 01/03/2019 Cabazitaxel and Prednisolone Genitourinary 101 Erlotinib Monotherapy Lung 219 Mifamurtide Sarcoma 100 PACLitaxel Monotherapy 80mg/m2 7day Breast 226 Gastrointestinal 226 Gynaecology 226 Modified FOLFOX-6 Therapy-14 day Gastrointestinal 209 FOLFOX-4 Therapy-14 day Gastrointestinal 210 FOLFIRI Therapy-14 day Gastrointestinal 227 (*rituximab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) 08/03/2019 Therapy 21 days (R*)-CHOP 21 days Lymphoma and Mye 307 CHOEP Therapy 21 days Lymphoma and Mye 396 Fludarabine, Cyclophosphamide and rituximab (FC IV+R) Therapy Leukaemia/BMT 241 Fludarabine, Cyclophosphamide and rituximab (FC Oral+R) Therapy Leukaemia/BMT 410 Nordic Therapy Protocol Lymphoma and Mye 393 15/03/2019 Lenvatinib Therapy Head & Neck 295 R-CHOP-14 days Lymphoma and Mye 409 05/04/2019 rituximab and Bendamustine Therapy Lymphoma and Mye 345 Bortezomib, Lenalidomide and 02/05/2019 Dexamethasone (RVD) Therapy- 21 day Lymphoma and Mye 416 CARBOplatin (AUC 2) Weekly with 11/05/2019 Radiotherapy (RT) Head & Neck 419 Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle Head & Neck 418

Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 11/05/2019 day cycle Head & Neck 417 5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day Gastrointestinal 421 30/05/2019 Bevacizumab 10mg/kg-14days Breast 212 Gastrointestinal 212 Genitourinary 212 Gynaecology 212 Bevacizumab 15mg/kg - 21 days Breast 215 Gastrointestinal 215 Gynaecology 215 Lung 215 Bevacizumab 5mg/kg - 14 days Gastrointestinal 211 Bevacizumab 7.5mg/kg-21days Gastrointestinal 214 Lung 214 DOCEtaxel Monotherapy 100mg/m2 21 day cycle Breast 202 DOCEtaxel Monotherapy 75mg/m2 21 day cycle Genitourinary 203 Lung 203 Panitumumab 6mg/kg Therapy Gastrointestinal 225 Trastuzumab (IV) Monotherapy 21 days Breast 200 DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day Breast 250 DOXOrubicin, Cyclophosphamide 20/06/2019 followed by weekly PACLitaxel Therapy Breast 260 DOXOrubicin, Cyclophosphamide followed by weekly PACLitaxel Therapy (AC-T) Breast 260 epirubicin 75 + Cyclophosphamide (EC75) Therapy Breast 263 epirubicin 90 + Cyclophosphamide (EC90) Therapy Breast 262 Oral Vinorelbine Monotherapy-7days Breast 259 Lung 259 epirubicin, CISplatin and 5-FU (ECF) 01/07/2019 Therapy Gastrointestinal 240 epirubicin, Oxaliplatin and Capecitabine (EOX) Therapy Gastrointestinal 239 Tretinoin (ATRA)/Idarubicin (PETHEMA 03/07/2019 AIDA) Induction Therapy Leukaemia/BMT 366 CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with 07/07/2019 Radiotherapy (RT) -5 weeks Gastrointestinal 422

07/07/2019 28/07/2019 DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle Breast 423 Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen Gastrointestinal 427 QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly Gastrointestinal 428 Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days Breast 430 (R**)-ICE ((rituximab), Ifosfamide, CARBOplatin and Etoposide) Therapy Lymphoma and Mye 397 BEAM Autologous Transplant Conditioning Protocol Lymphoma and Mye 408 epirubicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day Gastrointestinal 429 DA(60/100) 3+10: Course 1 Induction Therapy (AML-17) Leukaemia/BMT 359 DA (50/100) (3+8) Course 2 Induction Therapy (AML-17) Leukaemia/BMT 360 Intermediate Dose Cytarabine Therapy Leukaemia/BMT 364 High Dose Cytarabine Therapy Leukaemia/BMT 365 (R**)-DHAP Therapy Lymphoma and Mye 395 08/09/2019 Ibrutinib Therap (Mantly Cell Lymphoma) Lymphoma and Mye 297 Decitabine Monotherapy AML (28 day 11/09/2019 cycle) Leukaemia/BMT 231 Ibrutinib Therap (CLL/ Waldenstrom's Macroglobulinaemia) Leukaemia/BMT 296 Obinutuzumab and Chlorambucil 20/09/2019 Therapy Lymphoma and Mye 286 Pixantrone Therapy Lymphoma and Mye 255 Trastuzumab Emtansine (Kadcyla ) - 21 days Breast 206 Trastuzumab SC 21 days-early Breast Cancer Breast 285 Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma Breast 272 DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days Breast 258 Siltuximab Monotherapy Lymphoma and Mye 277 CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day Lung 279

CISplatin (75mg/m2) + Etoposide Therapy- 20/09/2019 21 day Lung 280 27/09/2019 CARBOplatin Monotherapy-28 days Breast 251 DOXOrubicin and Cyclophosphamide Breast 252 CARBOplatin (AUC4-6) Monotherapy-28 days Gynaecology 251 CARBOplatin (AUC4-6) Monotherapy-21 29/09/2019 days Breast 261 Gynaecology 261 02/10/2019 Alectinib Monotherapy Lung 401 06/10/2019 FLOT Therapy-14 day Gastrointestinal 344 Nivolumab Ipilimumab Combination 09/10/2019 Therapy Skin/Melanoma 431 Nivolumab Monotherapy Skin/Melanoma 349 Nivolulmab Monotherapy Genitourinary 349 Lymphoma and Mye 349 DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab 23/10/2019 Therapy (AC-TH) Breast 432 Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Breast 433 Pazopanib Therapy Genitourinary 445 Sarcoma 445 Bevacizamab 5mg/kg and Modified FOLFOX-6 Therapy-14 day Gastrointestinal 446 Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy 14 day Gastrointestinal 447 Panitumumab 6mg/kg and FOLFIRI Therapy 14 day Gastrointestinal 448 Bevacizumab 5mg/kg and FOLFIRI Therapy 14 days Gastrointestinal 449 Procarbazine Lomustine and VinCRIStine 26/10/2019 (PCV) Therapy Neuro-oncology 379 Obinutuzumab and Bendamustine 01/11/2019 Therapy-28 day cycle Lymphoma and Mye 424 Obinutuzumab Maintenance Therapy following O-Bendamustine therapy Lymphoma and Mye 425 Vismodegib Monotherapy Skin/Melanoma 236 02/11/2019 Olaparib Monotherapy Gynaecology 341 Gemcitabine + CARBOplatin (AUC 4) 15/11/2019 Therapy-21days Gynaecology 306 Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy Breast 265

5-Fluorouracil, epirubicin 50 and 15/11/2019 Cyclophosphamide (FEC50) Therapy Breast 269 Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T) Breast 278 Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day Lung 281 Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day Genitourinary 282 Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day Gynaecology 306 Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day Genitourinary 310 Lung 310 Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day Gastrointestinal 383 EriBULlin Monotherapy Breast 228 5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy Breast 265 5-Fluorouracil and mitomycin 17/11/2019 Chemoradiation Therapy Genitourinary 450 5-Fluorouracil (4 day) and mitomycin Chemoradiation Therapy Gastrointestinal 451 R-CODOX-M Therapy (Patients less than or equal to 65 years) Lymphoma and Mye 398 R-IVAC Therapy (Patients less than or equal to 65 years) Lymphoma and Mye 399 R-CODOX-M Therapy (Patients greater than 65 years) Lymphoma and Mye 403 R-IVAC Therapy (Patients greater than 65 years) Lymphoma and Mye 404 Bleomycin, Etoposide and CISplatin 06/12/2019 Therapy Genitourinary 300 CISplatin (40mg/m2) Weekly with Radiotherapy (RT) Genitourinary 385 Gynaecology 385 Head & Neck 385 DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle Sarcoma 420 Etoposide and CISplatin 20mg/m2 (EP) Therapy Genitourinary 301 CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day Lung 271

Gemcitabine (1000mg/m2) Monotherapy 06/12/2019-56 day Gastrointestinal 283 Gemcitabine (1000mg/m2) Monotherapy - 28 day Gastrointestinal 284 Lung 284 Vemurafenib Monotherapy Skin/Melanoma 102 Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days 11/12/2019 Therapy Genitourinary 333 Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days Genitourinary 338 Vinorelbine and CISplatin Therapy-21 days Lung 339 18/12/2019 Dose Adjusted R-EPOCH Therapy Lymphoma and Mye 355 TICE -Autologous Conditioning Germ Cell Tumour Regimen Genitourinary 437 CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen Genitourinary 453 CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day Lung 456 26/01/2020 Crizotinib Monotherapy Lung 243 27/01/2020 Crizotinib Monotherapy Lung 243 28/01/2020 Crizotinib Monotherapy Lung 243 07/02/2020 Cetuximab Monotherapy-7 days Gastrointestinal 207 Head & Neck 207 EMA/CO Therapy Gynaecology 248 Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy Gynaecology 264 Methotrexate 8 day Charing Cross Regimen Gynaecology 246 Trastuzumab (IV) Monotherapy 7 days Breast 201 DACTINomycin Therapy Gynaecology 247 Nab-PACLitaxel (Abraxane ) and 10/02/2020 Gemcitabine 28 day Gastrointestinal 256 (blank) (blank) (blank) (blank) Grand Total